Consensus Damora Therapeutics, Inc.

Stocks

DMRA

KYG2646Y1044

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2026-07-30 EDT			5-day change	1st Jan Change
29.21 ^USD	+3.11%		+0.14%	+26.94%

07-29	Wedbush Adjusts Damora Therapeutics Price Target to $40 From $35, Maintains Outperform Rating	MT
07-27	Jefferies Initiates Coverage on Damora Therapeutics With Buy Rating, $50 Price Target	MT

Evolution of the Average Target: Damora Therapeutics, Inc.

Evolution of the Target Price: Damora Therapeutics, Inc.

Changes in Analyst Recommendations: Damora Therapeutics, Inc.

6e1.Qh5--UQnwA_2_oat4dS4_wDUO5dPB851C3po1Dn_lPU.J2kUwBZWk2ynzevPuLLsm2-hT_kNRpQXTk8uuk-Z_5dvZx-sMWuTQrWUtg~d29ead499039766a5b3667782017b53a

Analysts' recommendations: Damora Therapeutics, Inc.

07-29	Wedbush Adjusts Damora Therapeutics Price Target to $40 From $35, Maintains Outperform Rating	MT
07-27	Jefferies Initiates Coverage on Damora Therapeutics With Buy Rating, $50 Price Target	MT
06-11	HC Wainwright Initiates Damora Therapeutics at Buy With $45 Price Target	MT
06-08	TD Cowen Initiates Damora Therapeutics at Buy	MT
05-28	Wedbush Initiates Damora Therapeutics at Outperform With $35 Price Target	MT
04-24	Damora Faces Upside As Fast-Follower CALR 'Should Make Bigger Splash,' RBC Says	MT
04-24	RBC Initiates Damora Therapeutics at Outperform, Speculative Risk With $40 Price Target	MT
12-01	Guggenheim Initiates Coverage on Galecto With Buy Rating, $32 Price Target	MT
24-06-10	Oppenheimer Adjusts Price Target on Galecto to $9 From $10, Maintains Outperform Rating	MT
23-09-28	HC Wainwright Downgrades Galecto to Neutral From Buy	MT
23-08-21	HC Wainwright Adjusts Price Target on Galecto to $2 From $12, Maintains Buy Rating	MT
23-06-20	Oppenheimer Initiates Coverage on Galecto With Outperform Rating, $12 Price Target	MT
23-03-17	Cantor Fitzgerald Initiates Galecto at Overweight With $16 Price Target	MT
22-08-03	SVB Securities Adjusts Galecto's Price Target to $13 from $16, Keeps Outperform Rating	MT
22-02-14	Credit Suisse Trims Galecto's Price Target to $6 from $7, Maintains Outperform Rating	MT
21-08-06	GALECTO : Credit Suisse Lowers Galecto's PT to $7 from $12 on Lower Projected Sales for GB0139, Reduced Near-Term M&A Expectations; Keeps Outperform Rating	MT
21-03-16	GALECTO : Credit Suisse Lowers Galecto's PT to $12 from $29 After Recommendation to End Parts of GB0139 Phase 2 Study, Keeps Outperform Rating	MT
21-03-16	GALECTO : SVB Leerink Adjusts Galecto's Price Target to $16 From $27, Keeps Outperform Rating	MT
20-11-23	GALECTO : Credit Suisse Initiates Coverage on Galecto With Outperform Rating, $29 Price Target	MT
20-11-23	GALECTO : BofA Securities Initiates Coverage on Galecto With Buy Rating, $21 Price Target	MT
20-11-23	GALECTO : SVB Leerink Starts Galecto at Outperform With $27 Price Target	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	DAMORA THERAPEUTICS, INC.					+52.92%
	WUXI APPTEC CO., LTD.					+19.92%
	ARGENX SE					+20.09%
	BIONTECH SE					+31.37%
	INSMED INCORPORATED					+93.3%
	WUXI BIOLOGICS (CAYMAN) INC.					+24.59%
	GENMAB A/S					+29.72%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+17.9%
	EXELIXIS, INC.					-6.97%
	PHARMAESSENTIA CORPORATION					+4.71%
	Average					+28.75%
	Weighted average by Cap.					+26.76%